Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib

Clin Lymphoma Myeloma Leuk. 2024 Feb 29:S2152-2650(24)00092-2. doi: 10.1016/j.clml.2024.02.014. Online ahead of print.

Authors

Fadi G Haddad¹, Cedric Nasnas², Koji Sasaki², Shilpa Paul², Ghayas C Issa², Caitlin Rausch², Elias Jabbour², Hagop Kantarjian²

Affiliations

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: fhaddad@mdanderson.org.
² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

PMID: 38503634
DOI: 10.1016/j.clml.2024.02.014

No abstract available

Keywords: Antacid; H2 blocker; Response; Tyrosine kinase inhibitor.

Publication types

Letter